PRESS RELEASE: Interim Analysis Shows At Least 90% Chance of Statistically Significant Difference in PTSD Symptoms after MDMA-assisted Psychotherapy

An interim analysis of data from the first of MAPs’ two Phase 3 clinical trials of MDMA-assisted psychotherapy for posttraumatic stress disorder revealed a 90% or greater probability that the trial will detect statistically significant results when all participants have been treated, and that the trial will not require additional participants beyond the first 100. This is the best-case scenario for an interim analysis and suggests that MAPS’ research program is on track for approval by the U.S. Food and Drug Administration (FDA).

Click here to read the full release.